Sponsor & Developer Portfolio
Emergent BioSolutions
Clinical development pipeline, platform architecture, and registered trial tracking for Emergent BioSolutions vaccine candidates.
4
Candidates
4
Target Diseases
3
Linked Studies
Development Phase Distribution
Discontinued / Inactive: 3 Approved / Licensed: 1
Platform Technologies
Biological (unspecified platform): 3 See FDA product page / label: 1
Target Pathogens & Indications
Adenoviral Infection Anthrax HIV Hepatitis B
Vaccine Pipeline Candidates (4)
Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.
Approved / Licensed
fda-cyfendus
CYFENDUS
Target: Anthrax
Platform: See FDA product page / label
Key Milestone: US-licensed — see product label / ACIP for use; further supplements may expand indication
Discontinued / Inactive
ctgov-ad4-mgag-emergent-biosolutions
Ad4-mgag
Target: HIV
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2017-02 (registry estimate)
Discontinued / Inactive
ctgov-pxvx0047-vaccine-emergent-biosolutions
PXVX0047 Vaccine
Target: Adenoviral Infection
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2017-11-27 (registry estimate)
Discontinued / Inactive
ctgov-hepatitis-b-vaccine-emergent-biosolutions
hepatitis B vaccine
Target: Hepatitis B
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2011-03-11 (registry estimate)
Explore Other Vaccine Developers & Sponsors
Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.